BioPlus Acquisition Corp.
BIOSW
NASDAQ Global Market0.00
USD
+0.00
- -
CIK
0001856653
CUSIP
G11217125
Return %
Stock
S&P500
1Y
-98.21
18.21
3Y
-99.53
63.29
5Y
-99.53
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jonathan M. N. Rigby MBA
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 260 Madison Avenue New York City NY United States of America 10016
- IPO Date
- Jan 24, 2022
- CIK
- 0001856653
- Website
- bioplusspac.com
- Similar Companies
- Business
- BioPlus Acquisition Corp. (BIOSW) is a blank check company formed to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the life sciences and healthcare industries. The company offers no current products or services beyond its SPAC structure, which facilitates such transactions through public shares, units, and warrants traded on Nasdaq; it operates without significant ongoing operations or revenue generation. Incorporated in 2021 and headquartered at 260 Madison Avenue, Suite 800, New York, New York, BioPlus focuses its search for targets across the United States, European Union, Israel, and Australasia, with potential customers including investors and life sciences entities. In May 2023, BioPlus entered a definitive business combination agreement with Avertix Medical, Inc., valuing the combined entity at approximately $195 million enterprise value and targeting a Nasdaq listing under the name Avertix Medical; however, the parties mutually terminated this agreement on October 4, 2023. Following the termination, BioPlus announced its intention to liquidate as soon as practicable, redeeming all public shares at an estimated $10.79 per share while warrants expire worthless, with the sponsor waiving redemption rights for certain founder shares.